tbuckley/cabot-search huggingface dataset:
Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach
Authors: John G Hanly, Murray B Urowitz, Caroline Gordon, Sang-Cheol Bae, Juanita Romero-Diaz, Jorge Sanchez-Guerrero, Sasha Bernatsky, Ann E Clarke, Daniel J Wallace, David A Isenberg, Anisur Rahman, Joan T Merrill, Paul R Fortin, Dafna D Gladman, Ian N Bruce, Michelle Petri, Ellen M Ginzler, Mary Anne Dooley, Rosalind Ramsey-Goldman, Susan Manzi, Andreas Jönsen, Graciela S Alarcón, Ronald F van Vollenhoven, Cynthia Aranow, Meggan Mackay, Guillermo Ruiz-Irastorza, Sam Lim, Murat Inanc, Kenneth C Kalunian, Søren Jacobsen, Christine A Peschken, Diane L Kamen, Anca Askanase, Vernon Farewell
Journal: Annals of the Rheumatic Diseases (2020)

Objectives Using a reversible multistate model, we prospectively examined neuropsychiatric (NP) events for attribution, outcome and association with health-related quality of life (HRQoL), in an international, inception cohort of systemic lupus erythematosus (SLE) patients. Methods Annual assessments for 19 NP events attributed to SLE and non-SLE causes, physician determination of outcome and patient HRQoL (short-form (SF)-36 scores) were measured. Time-to-event analysis and multistate modelling examined the onset, recurrence and transition between NP states. Results NP events occurred in 955/1827 (52.3%) patients and 592/1910 (31.0%) unique events were attributed to SLE. In the first 2 years of follow-up the relative risk (95% CI) for SLE NP events was 6.16 (4.96, 7.66) and non-SLE events was 4.66 (4.01, 5.43) compared with thereafter. Patients without SLE NP events at initial assessment had a 74% probability of being event free at 10 years. For non-SLE NP events the estimate was 48%. The majority of NP events resolved over 10 years but mortality was higher in patients with NP events attributed to SLE (16%) versus patients with no NPSLE events (6%) while the rate was comparable in patients with non-SLE NP events (7%) compared with patients with no non-SLE events (6%). Patients with NP events had lower SF-36 summary scores compared with those without NP events and resolved NP states (p&lt;0.001). Conclusions NP events occur most frequently around the diagnosis of SLE. Although the majority of events resolve they are associated with reduced HRQoL and excess mortality. Multistate modelling is well suited for the assessment of NP events in SLE.
Capsular glycan recognition provides antibody-mediated immunity against tuberculosis
Authors: Tingting Chen, Caroline Blanc, Yanyan Liu, Elise Ishida, Sarah Singer, Jiayong Xu, Maju Joe, Elizabeth R. Jenny-Avital, John Chan, Todd L. Lowary, Jacqueline M. Achkar
Journal: Journal of Clinical Investigation (2020)

A better understanding of all immune components involved in protecting against Mycobacterium tuberculosis infection is urgently needed to inform strategies for novel immunotherapy and tuberculosis (TB) vaccine development. Although cell-mediated immunity is critical, increasing evidence supports that antibodies also have a protective role against TB. Yet knowledge of protective antigens is limited. Analyzing sera from 97 US immigrants at various stages of M. tuberculosis infection, we showed protective in vitro and in vivo efficacy of polyclonal IgG against the M. tuberculosis capsular polysaccharide arabinomannan (AM). Using recently developed glycan arrays, we established that anti-AM IgG induced in natural infection is highly heterogeneous in its binding specificity and differs in both its reactivity to oligosaccharide motifs within AM and its functions in bacillus Calmette-Guérin vaccination and/or in controlled (latent) versus uncontrolled (TB) M. tuberculosis infection. We showed that anti-AM IgG from asymptomatic but not from diseased individuals was protective and provided data suggesting a potential role of IgG2 and specific AM oligosaccharides. Filling a gap in the current knowledge of protective antigens in humans, our data support the key role of the M. tuberculosis surface glycan AM and suggest the importance of targeting specific glycan epitopes within AM in antibody-mediated immunity against TB.
P-0040 The Double Cancer Consist of Gastric Cancer and Hematological Malignancy
Authors: Kazuhiko Natori, Susumu Ishihara, Daisuke Nagase, Akiko Shibuya, Yukitoshi Toyoda, Yoshinori Fujimoto, Kazutoshi Shibuya, Yasunobu Kuraishi, Haruka Izumi
Journal: Annals of Oncology (2012)
A Scoring System to Determine Patients’ Risk of Colectomy Within 1 Year After Hospital Admission for Acute Severe Ulcerative Colitis
Authors: Guillaume Le Baut, Julien Kirchgesner, Aurélien Amiot, Jérémie H. Lefevre, Najim Chafai, Cécilia Landman, Isabelle Nion, Anne Bourrier, Charlotte Delattre, Chloé Martineau, Harry Sokol, Phillipe Seksik, Yann Nguyen, Yoann Marion, Gil Lebreton, Franck Carbonnel, Stéphanie Viennot, Laurent Beaugerie, Lionel Arrive, Laurent Beaugerie, Anne Bourrier, Marine Camus, Najim Chafai, Ulriikka Chaput, Chloé Martineau, Laurence Cholley Monnier, Clotilde Debove, Xavier Dray, Jean-François Fléjou, Guillaume Le Gall, Nadia Hoyeau, Julien Kirchgesner, Cecilia Landman, Jérémie H. Lefevre, Philippe Marteau, Isabelle Nion-Larmurier, Violaine Ozenne, Yann Parc, Philippe Seksik, Harry Sokol, Magali Svrcek, Emmanuel Tiret
Journal: Clinical Gastroenterology and Hepatology (2020)
O-0015 Survival According to Prognostic Risk Factors in Patients Receiving First-Line Chemotherapy Plus Cetuximab in the Crystal and Opus Studies
Authors: Claus-Henning Köhne, Eric Van Cutsem, Carsten Bokemeyer, Michael Schlichting, Steffen Heeger, Gunnar Folprecht
Journal: Annals of Oncology (2012)
Phase II Three-Arm Randomised Study of the Braf Inhibitor (BRAFI) Dabrafenib Alone vs Combination with Mek1/2 Inhibitor (MEKI) Trametinib in Pts with Braf V600 Mutation-Positive Metastatic Melanoma (MM)
Authors: G.V. Long, J.A. Sosman, A.I. Daud, J.S. Weber, K.T. Flaherty, J.R. Infante, O. Hamid, L. Schuchter, J.S. Cebon, I. Puzanov, A.P. Algazi, R. Kudchakar, K. Lewis, W. Hwu, R.F. Kefford, P. Sun, S.M. Little, R. Gonzalez, K. Patel, K.B. Kim
Journal: Annals of Oncology (2012)
Fatty liver disease: putting the spotlight on a silent menace for young adults
Authors: Elisabetta Bugianesi
Journal: The Lancet. Gastroenterology & hepatology (2020)

One of the processes that drives progression to cirrhosis involves fat accumulation in the liver related to alcohol or obesity—namely alcohol-related fatty liver disease and non-alcoholic fatty liver disease (NAFLD)—with identical histological patterns. In this issue of The Lancet Gastroenterology & Hepatology, Kushala W M Abeysekera and colleagues 1 Abeysekera KWM Fernandes GS Hammerton G et al. Prevalence of steatosis and fibrosis in young adults in the UK: a population-based study. Lancet Gastroenterol Hepatol. 2020; (published online Jan 15)https://doi.org/10.1016/S2468-1253(19)30419-4 Summary Full Text Full Text PDF PubMed Scopus (27) Google Scholar present an insightful report on the threat of fatty liver disease in young adults aged 22–26 years enrolled in the Avon Longitudinal Study of Parents and Children (ALSPAC). One in five of the young participants had a fatty liver, severe in almost half of cases, and one in forty had evidence of liver fibrosis. Alcohol intake, even when hazardous (Alcohol Use Disorders Identification Test-C score ≥5) or of a level equivalent to alcohol use disorder, was not a significant determinant of steatosis, which was mainly linked to obesity (based on body-mass index [BMI]) and visceral obesity (based on waist-to-height ratio), and to the presence of metabolic syndrome, and thus ultimately attributable to NAFLD. The study has the unquestionable merit of highlighting the burden of NAFLD in young adults; furthermore, it confirms the amplificatory synergy of alcohol and obesity on liver fibrogenesis, while disproving the hypothesis of a beneficial effect of moderate alcohol consumption in NAFLD. 2 Dunn W Sanyal AJ Brunt EM et al. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol. 2012; 57: 384-391 Summary Full Text Full Text PDF PubMed Scopus (169) Google Scholar Prevalence of steatosis and fibrosis in young adults in the UK: a population-based studyOne in five young people had steatosis and one in 40 had fibrosis around the age of 24 years. The risk of fibrosis appears to be greatest in young adults who have harmful drinking patterns and steatosis. A holistic approach to the UK obesity epidemic and excessive drinking patterns is required to prevent an increasing health-care burden of adults with advanced liver disease in later life. Full-Text PDF Open Access
Infra-Centimetric HER2 Positive Breast Cancer: The Southern Italy Experience
Authors: G.R.R. Ricciardi, B. Adamo, M. Caruso, C. Iacono, G. Blanco, N. Borsellino, L. Blasi, R. Bordonaro, G. Tuccari, V. Adamo
Journal: Annals of Oncology (2012)
Abstract 434: A Randomized Blinded Trial of Three Chest Compression Strategies in a Porcine Model of Pediatric Cardiac Arrest
Authors: James J Menegazzi, David D Salcido, Allison C Koller, Cornelia Genbrugge, Ericka L Fink, Robert A Berg, Charity G Patterson
Journal: Circulation (2019)

Background: Current guidelines recommend that chest compressions for children be done at either 1.5 inches depth and 100 per minute, or one-third the chest A-P diameter depth and 100 per minute. Neither of these recommendations is based on scientific evidence. Objective: As part of an ongoing efficacy trial, we sought to compare the safety of three different chest compression strategies in a porcine model of pediatric cardiac arrest. Methods: Following anesthesia, instrumentation, and induction of asphyxial cardiac arrest, we randomly assigned 48 domestic swine to one of three groups (n=16 per group). The mean mass of 25.7 kg approximates the 50 th percentile for a 7 year old. Group 1 had fixed chest compression depth of 1.5 inches/rate 100; group 2 had fixed proportional depth of one-third the A-P diameter/rate 100; group 3 used an adaptive algorithm that incrementally increased chest compression rate and/or depth from baseline 1.5in (max: 2.13in) and 100/min (max; 130/min) every 25s while coronary perfusion pressure was below 25mmHg. Necropsies were independently performed by a veterinarian and veterinary technologist who were blinded to group assignment. The primary safety outcome was unrecoverable injury (i.e. toxicity), which we defined as either a total lung injury score ≥16 (score can range from 0 to 20) plus presence of hemothorax, or disruption of either the aorta or vena cava. Data were analyzed with the Bayesian Beta Binomial to determine if within-group toxicity exceeded an unacceptable level (30%) with a pre-selected posterior predictive threshold of 0.75(ptox). Lung injury scores between groups were compared with Kruskal-Wallis tests. Results: Median total lung injury scores were: 12 for group 1; 18 for group 2; 14 for group 3. Group 2 was significantly different from both groups 1 and 3 (p&lt;0.001). Groups 1 and 3 did not differ (p=0.24). Toxicity occurred in zero animals in group 1 (ptox=0.0001); 7 animals in group 2 (ptox=0.8180); and 1 animal in group 3 (ptox=0.0076). The posterior probability threshold was exceeded in group 2 which warranted termination of the treatment arm for safety. Conclusions: Chest compressions performed at a depth of one-third the A-P diameter are unsafe. The safety of this approach in children should be carefully evaluated.
Cognitive behavioral therapy or graded exercise therapy compared with usual care for severe fatigue in patients with advanced cancer during treatment: a randomized controlled trial
Authors: H. Poort, M.E.W.J. Peters, W.T.A. van der Graaf, P.T. Nieuwkerk, A.J. van de Wouw, M.W.G. Nijhuis-van der Sanden, G. Bleijenberg, C.A.H.H.V.M. Verhagen, H. Knoop
Journal: Annals of Oncology (2020)
Cytology Samples (S) for EGFR and KRAS Mutation (MUT) Testing in Non-Small-Cell Lung Cancer (NSCLC). Experience from a Single Institution
Authors: T. Moran Bueno, E. Castella Fernandez, M. Tierno Garcia, C. Buges Sanchez, C. Queralt Herrero, M. Perez Cano, D. Naranjo Hans, F. Andreo Garcia, L. Capdevila Riera, R. Rosell
Journal: Annals of Oncology (2012)
Phase 1 Study of Bpm 31510 (UBIDECARANONE) in Advanced Solid Tumors: Updated Analysis of a Novel Treatment with Promising Activity
Authors: S.P. Chawla, A. Hendifar, V.S. Chua, D. Quon, V. Narasimhan, Y. Lavinski, J. McCook, R. Sarangarajan, P. Song, N. Narain
Journal: Annals of Oncology (2012)
P3.07 Building the Organization Framework for Biopsy-Driven Translational Research: The Quebec Clinical Research Organization in Cancer (Q-Croc) Experience
Authors: Z. Diaz, T. Gagnon-Kugler, C. Rousseau, A. Aguilar-Mahecha, T. Alcindor, R. Aloyz, S. Assouline, M. Basik, D. Bachvarov, L. Bélanger, E. Camlioglu, M. Cartillone, B. Chabot, R. Christodoulopoulos, C. Courtemanche, A. Constantin, N. Benlimame, I. Dao, R. Dalfen, L. Gosselin, F. Habbab, M. Hains, T. Haliotis, T.H. Nielsen, M. Joncas, P. Kavan, R. Klink, A. Langlaben, M. Lebel, B. Lespérance, K. Mann, J. Masson, P. Metrakos, S. McNamara, W.H. Miller, M. Orain, L. Panasci, E. Paquet, M. Phillie, S. Qureshi, D. Rodrigue, A. Salman, A. Spatz, B. Têtu, A. Tosikyan, M. Tsatoumas, T. Vuong, G. Batist
Journal: Annals of Oncology (2012)
Study on Association of Polymorphism of CYP P 450 2d6 with Head and Neck Cancer and Treatment Response in Patients Receiving Neoadjuvant Chemotherapy (TPF) Followed by Chemoradiation
Authors: D. Kumar, M.C. Pant, N. Jamal, D. Parmar, S. Kumar, S. Singh, M. Bhatt
Journal: Annals of Oncology (2012)
Social Media– and Internet-Based Disease Surveillance for Public Health
Authors: Allison E. Aiello, Audrey Renson, Paul N. Zivich
Journal: Annual Review of Public Health (2020)

Disease surveillance systems are a cornerstone of public health tracking and prevention. This review addresses the use, promise, perils, and ethics of social media– and Internet-based data collection for public health surveillance. Our review highlights untapped opportunities for integrating digital surveillance in public health and current applications that could be improved through better integration, validation, and clarity on rules surrounding ethical considerations. Promising developments include hybrid systems that couple traditional surveillance data with data from search queries, social media posts, and crowdsourcing. In the future, it will be important to identify opportunities for public and private partnerships, train public health experts in data science, reduce biases related to digital data (gathered from Internet use, wearable devices, etc.), and address privacy. We are on the precipice of an unprecedented opportunity to track, predict, and prevent global disease burdens in the population using digital data.
Cytokeratin (CK) 8 Expression in Non-Small-Cell Lung Cancer (NSCLC) and its Relation to Tumor Invasiveness and Patient Survival
Authors: A. Kubo, N. Kanaji, S. Bandoh, T. Ishii, J. Fujita, T. Matsunaga, E. Yamaguchi
Journal: Annals of Oncology (2012)
Dnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis
Authors: Xiaotian Zhang, Xinyu Wang, Xue Qing David Wang, Jianzhong Su, Nagireddy Putluri, Ting Zhou, Ying Qu, Mira Jeong, Anna Guzman, Carina Rosas, Yun Huang, Arun Sreekumar, Wei Li, Margaret A. Goodell
Journal: Blood (2020)
Ipilimuamb Treatment after Electrochemotherapy Could be An Effective Sequential Combination Approach
Authors: E. Simeone, L. Benedetto, G. Gentilcore, C. Caracò, G. Di Monta, U. Marone, A.M. Grimaldi, S. Mori, N. Mozzillo, P.A. Ascierto
Journal: Annals of Oncology (2012)
Second-Line Erlotinib Therapy in Elderly Patients with Advanced Non-Small-Cell Lung Cancer: IFCT-0501 Randomised, Phase 3 Trial
Authors: E. Quoix, V. Westeel, J. Oster, E. Pichon, J. Dauba, D. Debieuvre, L. Baudrin, F. Morin, B. Milleron, G. Zalcman
Journal: Annals of Oncology (2012)
Randomized Phase II Study of Concurrent Gefitinib Plus Chemotherapy Versus Alternation of Gefitinib and Chemotherapy in Previously Untreated Non-Small Cell Lung Cancer (NSCLC) with Sensitive EGFR Mutations: NEJ005/TCOG0902
Authors: S. Oizumi, J. Sakakibara-Konishi, A. Inoue, K. Kobayashi, A. Gemma, H. Yoshizawa, H. Isobe, Y. Saijyo, Y. Ishii, S. Morita, K. Hagiwara, T. Nukiwa
Journal: Annals of Oncology (2012)
Prevalence, Clinical Features and Prognosis of Diffuse Malignant Peritoneal Mesothelioma (DMPM): Do Patients in Clinical Trials Reflect the real World?
Authors: F. Grosso, D. Degiovanni, A. Roveta, S. Barbero, R. Libener, F. Musante, O. Testori, D. Mirabelli, P.G. Betta, M. Botta
Journal: Annals of Oncology (2012)
Bolero-2: A Randomized Phase III Study of Everolimus in Combination with Exemestane: Results of the Japanese Subgroup Analysis
Authors: Y. Ito, N. Masuda, H. Iwata, H. Mukai, J. Horiguchi, Y. Tokuda, K. Kuroi, H. Iwase, H. Inaji, S. Ohsumi, T. Nakayama, S. Ohno, T. Sahmoud, N. Ohno, S. Noguchi
Journal: Annals of Oncology (2012)
Significant Antitumor Activity of E-3810, a Novel FGFR and VEGFR Inhibitor, in Patients With FGFR1 Amplified Breast Cancer
Authors: R. Dienstmann, F. Andre, J. Soria, J. Tabernero, F.G.M. De Braud, R. Cereda, R. Bahleda, A. Hollebecque, A. Delmonte, M.G. Camboni
Journal: Annals of Oncology (2012)
Clinical Assessment of Cases of Hematological Malignancies Diagnosed by Image-Guided Needle Biopsy
Authors: J. Ishizawa, E. Matsuki, D. Abe, A. Yamane, H. Kunimoto, Y. Ono, N. Hashimoto, T. Kikuchi, M. Sakurai, K. Matsumoto, S. Nakatsuka, M. Inoue, J. Kato, Y. Miyakawa, S. Okamoto
Journal: Annals of Oncology (2012)
Association of Progression by Prostate Cancer Working Group (PCWG)-2 Criteria and Survival in Metastatic Castration Resistant Prostate Cancer
Authors: G. Sonpavde, G.R. Pond, A.J. Armstrong, M.D. Galsky, B.A. Wood, S. Wang, J. Paolini, M. Lechuga, M.R. Smith, M.D. Michaelson
Journal: Annals of Oncology (2012)
Tissue and Serum Biomarker Results from the Phase II Innovations Study in Non-Small Cell Lung Cancer (NSCLC)
Authors: N. Reinmuth, S.J. Scherer, R. Penzel, P. Schnabel, M. Meister, J. Kiemle-Kallee, A. Reuss, J.R. Fischer, M. Wolf, M. Thomas
Journal: Annals of Oncology (2012)
Heat Shock Protein 70 as a Biomarker of Clinical Outcomes After STEMI
Authors: Thomas Bochaton, Alexandre Paccalet, Pierre Jeantet, Claire Crola Da Silva, Régine Cartier, Cyril Prieur, Claire Jossan, Eric Bonnefoy-Cudraz, Nathan Mewton, Michel Ovize
Journal: Journal of the American College of Cardiology (2020)
A Phase I Dose Escalation and Bioequivalence Study of a Trastuzumab Biosimilar (FTMB) in Healthy Male Volunteers
Authors: L. Wisman, E. De Cock, J. Reijers, I. De Visser, M. De Kam, S. van Os, G. Voortman, L. Hooftman, K. Burggraaf
Journal: Annals of Oncology (2012)
Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening
Authors: Kenneth Offit, Kaitlyn A. Tkachuk, Zsofia K. Stadler, Michael F. Walsh, Hector Diaz-Zabala, Jeffrey D. Levin, Zoe Steinsnyder, Vignesh Ravichandran, Ravi N. Sharaf, Melissa K. Frey, Steven M. Lipkin, Mark E. Robson, Jada G. Hamilton, Joseph Vijai, Semanti Mukherjee
Journal: Journal of Clinical Oncology (2020)

Despite advances in DNA sequencing technology and expanded medical guidelines, the vast majority of individuals carrying pathogenic variants of common cancer susceptibility genes have yet to be identified. An alternative to population-wide genetic screening of healthy individuals would exploit the trend for genetic testing at the time of cancer diagnosis to guide therapy and prevention, combined with augmented familial diffusion or "cascade" of genomic risk information.
Zoonotic causes of febrile illness in malaria endemic countries: a systematic review
Authors: Jo E B Halliday, Manuela Carugati, Michael E Snavely, Kathryn J Allan, Julia Beamesderfer, Georgia A F Ladbury, Deborah V Hoyle, Paul Holland, John A Crump, Sarah Cleaveland, Matthew P Rubach
Journal: The Lancet Infectious Diseases (2020)
Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial
Authors: Paul Emery, Sarah Horton, Raluca Bianca Dumitru, Kamran Naraghi, Désirée van der Heijde, Richard J Wakefield, Elizabeth M A Hensor, Maya H Buch
Journal: Annals of the Rheumatic Diseases (2020)

Objectives We sought to confirm in very early rheumatoid arthritis (ERA) a much greater superiority (30%) of first-line etanercept+methotrexate (ETN+MTX) over treat-to-target MTX (MTX-TT) than previously reported in ERA (14%); and explore whether ETN following initial MTX secures a comparable response to first-line ETN+MTX. Methods Pragmatic, open-label, randomised controlled trial of treatment-naïve ERA (≤12 months symptom), Disease Activity Score 28 joint (DAS28)-erythrocyte sedimentation rate (ESR) ≥3.2, rheumatoid factor (RF)+/−anticitrullinated peptide antibody (ACPA) positive or ultrasound power Doppler (PD) if RF and ACPA negative. Subjects were randomised 1:1 to ETN+MTX; or MTX-TT, escalated to ETN if week 24 DAS28-ESR ≥2.6 and intramuscular corticosteroid at protocolised time points. Primary endpoint of week 48 DAS28ESR remission with clinical and imaging secondary endpoints. Results We randomised 120 patients, 60 to each arm (71% female, 73% RF/84% ACPA positive, median (IQR) symptom duration 20.3 (13.1, 30.8) weeks; mean (SD) DAS28 5.1 (1.1)). Remission rates with ETN+MTX and MTX-TT, respectively, were 38% vs 33% at week 24; 52% vs 38% at week 48 (ORs 1.6, 95% CI 0.8 to 3.5, p=0.211). Greater, sustained DAS28-ESR remission observed with ETN+MTX versus MTX-TT (42% and 27%, respectively; p=0.035). PD was fully suppressed by week 48 in over 90% in each arm. Planned exploratory analysis revealed OR 2.84, 95% CI 0.8 to 9.6) of achieving remission after 24 weeks of ETN administered first line compared with administered post-MTX. Conclusions Compared with remission rates typically reported with first-line tumour necrosis factor inhabitor+MTX versus MTX-TT, we did not demonstrate a larger effect in very ERA. Neither strategy conferred remission in the majority of patients although ultrasound confirmed local inflammation suppression. Poorer ETN response following failure of MTX-TT is also suggested. Trial registration number NCT02433184